Wedbush Maintains Outperform on Immunic, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides maintains an Outperform rating on Immunic (NASDAQ:IMUX) and raises the price target from $5 to $7.
October 10, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst maintains Outperform rating on Immunic and raises the price target from $5 to $7.
The news is directly related to Immunic and is likely to have a positive impact on its stock price. The Outperform rating indicates that the analyst expects the stock to do better than the market average. Furthermore, the increase in the price target from $5 to $7 suggests that the analyst sees potential for the stock's price to increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100